Replimune shares surge after US FDA agrees to reconsider skin cancer treatment rejected twice.
Replimune shares rose sharply after the US Food and Drug Administration agreed to reconsider the company's skin cancer treatment, which had previously been rejected twice.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near US
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Greenland mental distress rate jumps from 7% to 31% as Trump threats fuel crisis, study finds.
According to a study by a Greenland public health institute, the share of Greenlanders experiencing mental distress rose from 7% to 31% over the past year. The authors attribute the increase to the crisis caused by Trump's threats to seize the island.
UN health chief in DRC to battle Ebola meets authorities Friday, plans to visit violence-hit epicenter Saturday.
The UN health chief, in the Democratic Republic of Congo to help fight an Ebola outbreak, is set to meet Congolese authorities on Friday before heading Saturday to the violence-hit region at the center of the crisis.
Virginia: Bus strikes multiple vehicles, killing 5, injuring 34 - police
A bus struck multiple vehicles in Virginia, leaving five dead and 34 injured, according to police.
Former US AttorneyPam Bondi testifies before Congress in Epstein investigation.
Former US AttorneyPam Bondi testified before Congress in the investigation into Jeffrey Epstein.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.